Cargando…
Novel and Investigational Treatments for Onychomycosis
Onychomycosis is a common nail disease caused by fungi. The primary pathogens are dermatophytes; however, yeasts, non-dermatophyte moulds, and mixed fungal populations may also contribute to the development of a recalcitrant condition, usually accompanied by difficulties in everyday life and severe...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9604567/ https://www.ncbi.nlm.nih.gov/pubmed/36294644 http://dx.doi.org/10.3390/jof8101079 |
_version_ | 1784817846459564032 |
---|---|
author | Gregoriou, Stamatios Kyriazopoulou, Maria Tsiogka, Aikaterini Rigopoulos, Dimitrios |
author_facet | Gregoriou, Stamatios Kyriazopoulou, Maria Tsiogka, Aikaterini Rigopoulos, Dimitrios |
author_sort | Gregoriou, Stamatios |
collection | PubMed |
description | Onychomycosis is a common nail disease caused by fungi. The primary pathogens are dermatophytes; however, yeasts, non-dermatophyte moulds, and mixed fungal populations may also contribute to the development of a recalcitrant condition, usually accompanied by difficulties in everyday life and severe emotional stress. Treatment failure and relapse of the infection are the most frequent problems, though new issues have become the new challenges in the therapeutic approach to onychomycosis. Resistance to antifungals, an increasing number of comorbidities, and polydrug use among the ageing population are imperatives that impose a shift to safer drugs. Topical antifungals are considered less toxic and minimally interact with other drugs. The development of new topical drugs for onychomycosis is driven by the unmet need for effective agents with prolonged post-treatment disease-free time and a lack of systemic impact on the patients’ health. Efinaconazole, Tavaborole, and Luliconazole have been added to physicians’ weaponry during the last decade, though launched on the market of a limited number of countries. The pipeline is either developing new products (e.g., ME-1111 and NP213) with an appealing combination of pharmacokinetic, efficacy, and safety properties or reformulating old, well-known drugs (Terbinafine and Amphotericin B) by using new excipients as penetration enhancers. |
format | Online Article Text |
id | pubmed-9604567 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-96045672022-10-27 Novel and Investigational Treatments for Onychomycosis Gregoriou, Stamatios Kyriazopoulou, Maria Tsiogka, Aikaterini Rigopoulos, Dimitrios J Fungi (Basel) Review Onychomycosis is a common nail disease caused by fungi. The primary pathogens are dermatophytes; however, yeasts, non-dermatophyte moulds, and mixed fungal populations may also contribute to the development of a recalcitrant condition, usually accompanied by difficulties in everyday life and severe emotional stress. Treatment failure and relapse of the infection are the most frequent problems, though new issues have become the new challenges in the therapeutic approach to onychomycosis. Resistance to antifungals, an increasing number of comorbidities, and polydrug use among the ageing population are imperatives that impose a shift to safer drugs. Topical antifungals are considered less toxic and minimally interact with other drugs. The development of new topical drugs for onychomycosis is driven by the unmet need for effective agents with prolonged post-treatment disease-free time and a lack of systemic impact on the patients’ health. Efinaconazole, Tavaborole, and Luliconazole have been added to physicians’ weaponry during the last decade, though launched on the market of a limited number of countries. The pipeline is either developing new products (e.g., ME-1111 and NP213) with an appealing combination of pharmacokinetic, efficacy, and safety properties or reformulating old, well-known drugs (Terbinafine and Amphotericin B) by using new excipients as penetration enhancers. MDPI 2022-10-14 /pmc/articles/PMC9604567/ /pubmed/36294644 http://dx.doi.org/10.3390/jof8101079 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Gregoriou, Stamatios Kyriazopoulou, Maria Tsiogka, Aikaterini Rigopoulos, Dimitrios Novel and Investigational Treatments for Onychomycosis |
title | Novel and Investigational Treatments for Onychomycosis |
title_full | Novel and Investigational Treatments for Onychomycosis |
title_fullStr | Novel and Investigational Treatments for Onychomycosis |
title_full_unstemmed | Novel and Investigational Treatments for Onychomycosis |
title_short | Novel and Investigational Treatments for Onychomycosis |
title_sort | novel and investigational treatments for onychomycosis |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9604567/ https://www.ncbi.nlm.nih.gov/pubmed/36294644 http://dx.doi.org/10.3390/jof8101079 |
work_keys_str_mv | AT gregorioustamatios novelandinvestigationaltreatmentsforonychomycosis AT kyriazopouloumaria novelandinvestigationaltreatmentsforonychomycosis AT tsiogkaaikaterini novelandinvestigationaltreatmentsforonychomycosis AT rigopoulosdimitrios novelandinvestigationaltreatmentsforonychomycosis |